S SEAMLESS
LIVE

Serial Number

79408326

Owner

Seamless Therapeutics GmbH

Attorney

Brian J. Focarino

Filing Date

Dec 14, 2023

Add to watchlist:

No watchlists yet
View on USPTO

S SEAMLESS Trademark

Serial Number: 79408326 • Registration: 8237389

S SEAMLESS is a trademark filed by Seamless Therapeutics GmbH on December 14, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Seamless Therapeutics GmbH (2 trademarks)

Tatzberg 47/49

Entity Type: 99

Trademark Details

Filing Date

December 14, 2023

Registration Date

May 5, 2026

Published for Opposition

March 17, 2026

Goods & Services

Pharmaceutical and biological preparations for gene therapies and gene-editing therapies, all for the treatment of genetic and viral diseases; medical, pharmaceutical and biopharmaceutical preparations and substances containing programmable recombinases for the treatment of genetic and viral diseases; pharmaceutical goods and preparations, namely, gene transfer, regulation, modulation and delivery medications for the treatment of genetic and viral diseases and disorders; products, agents, for medical purposes, for veterinary purposes in the nature of pharmaceutical preparations for cellular, genome and gene editing therapies to treat genetic, oncological, immune system-related, and inflammatory disorders and diseases; genome editable enzymes being enzymes for medical purposes; DNA recombinant enzymes being enzymes for medical purposes; DNA editable enzymes, especially, recombinases and integrases being enzymes for medical purposes; genome editable enzymes for the treatment of diseases being enzymes for medical purposes; DNA recombinant enzymes for the treatment of diseases being enzymes for medical purposes; DNA editable enzymes, in particular recombinases and integrases, for the treatment of diseases being enzymes for medical purposes

Scientific and technological services, namely, product research and testing of pharmaceuticals for cell and gene therapies in the field of pharmaceutical product development for the creation of bioinformatic algorithms and models; development of pharmaceutical preparations and medicines, none of the foregoing for diagnostics; pharmaceutical product development, none of the foregoing for diagnostics; pharmaceutical products development of genome editable enzymes for treatment and not diagnostic purposes; pharmaceutical products development of DNA editable enzymes, in particular recombinases and integrases, for treatment and not diagnostic purposes

Chemicals for use in industry and science; biological preparations for use in industry and science, biological reagents, for use in industry and science, not for medical purposes

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 5, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
May 5, 2026 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 16, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 30, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 29, 2026 OPNR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 19, 2026 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 19, 2026 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 19, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 19, 2026 REAP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 17, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 17, 2026 PUBO
NOTIFICATION PROCESSED BY IB
Mar 12, 2026 GPNX
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 11, 2026 NONP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 25, 2026 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 24, 2026 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 18, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 18, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 18, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 18, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 18, 2026 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 13, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 13, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 13, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 15, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jul 15, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jul 15, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
May 21, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 21, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 21, 2025 TROA
REFUSAL PROCESSED BY IB
Dec 14, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 22, 2024 RFCS
REFUSAL PROCESSED BY MPU
Nov 22, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 15, 2024 RFCR
NON-FINAL ACTION WRITTEN
Nov 14, 2024 CNRT
ASSIGNED TO EXAMINER
Nov 5, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 4, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 4, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 31, 2024 REPR